HER2-amplified colorectal cancer

What changed: HER2-amplified colorectal cancer

Cancer page →

Every dated change on the records linked to HER2-amplified colorectal cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result3Milestone6This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordHER2-amplified colorectal cancer
Facts on this page last checked
When this page itself was last checked or edited.

2024 · 1

2024MilestoneTrastuzumab deruxtecan
Tumour-agnostic approval of trastuzumab deruxtecan for HER2 3+ solid tumours after DESTINY-CRC02
A milestone in how this cancer is treated.

2023 · 2

2022 · 2

2019 · 1

2019MilestoneMyPathway
MyPathway: trastuzumab plus pertuzumab active in HER2-amplified colorectal cancer
A milestone in how this cancer is treated.

2018 · 1

2018Trial resultMyPathway
MyPathway reported
Response in 23 percent of the first 230 patients; trastuzumab plus pertuzumab gave a 32 percent response rate in HER2-amplified colorectal cancer, now a guideline option; atezolizumab activity rose with tumour mutational burden.

2016 · 1

2016MilestoneTrastuzumab
HERACLES: trastuzumab plus lapatinib produces responses in 30 percent
A milestone in how this cancer is treated.

2011 · 1

2011MilestoneHER2
HER2 amplification identified as a cause of anti-EGFR resistance in patient-derived xenografts
A milestone in how this cancer is treated.